OSU-6162 is an investigational drug.
There have been 9 clinical trials for OSU-6162.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 20th 2023.
The most common disease conditions in clinical trials are Recurrence, Stress Disorders, Traumatic, and Stress Disorders, Post-Traumatic. The leading clinical trial sponsors are Ohio State University, VA Office of Research and Development, and San Diego Veterans Healthcare System.
There are two US patents protecting this investigational drug and one hundred and twenty-three international patents.